260 related articles for article (PubMed ID: 19075915)
1. Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Doepfner KT; Boller D; De Laurentiis A; Guerreiro AS; Marinov M; Arcaro A
Recent Pat DNA Gene Seq; 2007; 1(1):9-23. PubMed ID: 19075915
[TBL] [Abstract][Full Text] [Related]
2. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.
Guillermet-Guibert J; Bjorklof K; Salpekar A; Gonella C; Ramadani F; Bilancio A; Meek S; Smith AJ; Okkenhaug K; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8292-7. PubMed ID: 18544649
[TBL] [Abstract][Full Text] [Related]
3. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.
Arcaro A; Guerreiro AS
Curr Genomics; 2007 Aug; 8(5):271-306. PubMed ID: 19384426
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
5. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
6. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
8. Should individual PI3 kinase isoforms be targeted in cancer?
Jia S; Roberts TM; Zhao JJ
Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
[TBL] [Abstract][Full Text] [Related]
9. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
10. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
Rathinaswamy MK; Burke JE
Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT signaling pathway and cancer: an updated review.
Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
13. Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.
Pemberton JG; Stafford JL; Chang JP
Endocrinology; 2015 Jan; 156(1):218-30. PubMed ID: 25343277
[TBL] [Abstract][Full Text] [Related]
14. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
15. Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells.
Houslay DM; Anderson KE; Chessa T; Kulkarni S; Fritsch R; Downward J; Backer JM; Stephens LR; Hawkins PT
Sci Signal; 2016 Aug; 9(441):ra82. PubMed ID: 27531651
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
17. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
19. Galpha16 interacts with Class IA phosphatidylinositol 3-kinases and inhibits Akt signaling.
Yeung WW; Wong YH
Cell Signal; 2010 Sep; 22(9):1379-87. PubMed ID: 20471473
[TBL] [Abstract][Full Text] [Related]
20. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
Sujobert P; Bardet V; Cornillet-Lefebvre P; Hayflick JS; Prie N; Verdier F; Vanhaesebroeck B; Muller O; Pesce F; Ifrah N; Hunault-Berger M; Berthou C; Villemagne B; Jourdan E; Audhuy B; Solary E; Witz B; Harousseau JL; Himberlin C; Lamy T; Lioure B; Cahn JY; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Blood; 2005 Aug; 106(3):1063-6. PubMed ID: 15840695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
